Core Scientific, Inc. Tranche 2 Warrants financials
$16.67−5.50%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $164.2M | $115.2M | $79.8M | $81.1M | $78.6M | $79.5M | $94.9M | $95.4M | $141.1M | $179.3M |
| Gross profit | $70.0M | $30.1M | $20.8M | $3.9M | $5.0M | $8.2M | $4.8M | -$156.0K | $38.8M | $77.6M |
| Gross margin | 42.7% | 26.1% | 26.0% | 4.8% | 6.4% | 10.3% | 5.0% | −0.2% | 27.5% | 43.3% |
| Operating income | -$57.7M | -$297.3M | -$87.1M | -$80.5M | -$22.1M | -$47.0M | -$36.8M | -$40.9M | $7.4M | $60.7M |
| Net income | -$1.08B | -$342.4M | $190.5M | -$144.9M | -$13.3M | $448.9M | -$210.4M | -$343.4M | -$902.2M | $210.7M |
| Net margin | −658.4% | −297.1% | 238.9% | −178.6% | −16.9% | 564.5% | −221.6% | −360.2% | −639.4% | 117.5% |
| Diluted EPS | $-3.32 | $-1.06 | $0.70 | $-0.45 | $-0.04 | $1.24 | $-0.78 | $-1.17 | $-5.05 | $0.78 |
| EBITDA | -$254.0K | -$13.6M | -$56.7M | -$54.5M | -$3.4M | -$27.3M | -$12.8M | -$14.6M | $39.7M | $89.7M |
| Operating cash flow | -$18.9M | $249.9M | $157.5M | $131.8M | $34.0M | -$45.0M | $13.8M | $5.7M | $1.2M | $22.2M |
| Free cash flow | -$583.9M | -$139.3M | -$121.7M | -$112.7M | -$87.3M | -$129.0M | -$15.0M | -$25.5M | -$1.9M | -$9.7M |
| Diluted shares | 325.3M | 322.9M | 272.4M | 318.6M | 318.0M | 363.3M | 269.8M | 292.5M | 178.5M | 282.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.77B | $1.01B | $311.4M | $453.4M | $581.3M | $697.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $4.30B | $2.06B | $1.06B | $1.06B | $1.06B | $1.09B |
| Total assets | $5.26B | $3.07B | $2.35B | $2.17B | $1.85B | $1.50B |
| Total liabilities | $7.68B | $4.38B | $3.31B | $3.42B | $3.04B | $1.80B |
| Shareholders' equity | -$2.42B | -$1.31B | -$962.7M | -$1.25B | -$1.19B | -$297.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology